Pregnancy Epilepsy & Asthma — MRCP Part 1
- Crack Medicine

- 2 days ago
- 3 min read
TL;DR
For MRCP Part 1, pregnancy combined with epilepsy or asthma is a high-yield topic centred on drug safety, maternal–foetal risk, and acute management. The exam frequently tests avoiding teratogenic antiepileptics (notably valproate), continuing asthma therapy, and prioritising maternal stability. Expect single-best-answer questions focused on practical decision-making.
Why this matters
Pregnancy questions in MRCP Part 1 are designed to test safe clinical reasoning rather than memorisation alone. Epilepsy and asthma are commonly examined because they require balancing maternal disease control against foetal safety.
A key principle across both conditions is:
Poor disease control is often more dangerous than medication exposure.
Understanding this concept prevents common exam errors and mirrors real-world clinical decision-making.
For structured revision, begin with the MRCP Part 1 overview and integrate this topic into your systems-based study plan.
Core sections
1. Epilepsy in pregnancy — key principles
Continue antiepileptic drugs (AEDs)
Avoid abrupt withdrawal → risk of status epilepticus
Use monotherapy at the lowest effective dose
Prescribe high-dose folic acid (5 mg daily) preconception and during early pregnancy
Monitor serum drug levels (especially lamotrigine)
👉 Exam insight: Seizures → maternal hypoxia → foetal hypoxia. This is often more harmful than medication exposure.
2. Teratogenic antiepileptics — must know
Drug | Key Risk | Exam Relevance |
Sodium valproate | Neural tube defects, autism risk | Most tested — avoid |
Carbamazepine | Neural tube defects | Moderate risk |
Phenytoin | Foetal hydantoin syndrome | Dysmorphism |
Topiramate | Cleft lip/palate | Increasingly tested |
Lamotrigine | Low risk | Preferred option |
👉 Single best answer favourite: Safest AED in pregnancy = lamotrigine
3. Acute seizure management in pregnancy
Management is unchanged from non-pregnant patients:
First-line: IV benzodiazepine (e.g., lorazepam)
Second-line: levetiracetam or phenytoin
Maintain airway and oxygenation
👉 Never delay treatment due to pregnancy.
4. Asthma in pregnancy — key principle
Continue standard asthma therapy.
Poor control → ↑ risk of:
Preterm birth
Low birth weight
Pre-eclampsia
👉 The exam frequently tests inappropriate discontinuation of inhalers.
5. Safe asthma medications
Class | Example | Safety in Pregnancy |
SABA | Salbutamol | Safe |
ICS | Beclometasone | Safe (first-line preventer) |
LABA | Salmeterol | Safe |
Oral steroids | Prednisolone | Safe when required |
👉 Exam pearl: Inhaled corticosteroids must NOT be stopped.
6. Acute asthma exacerbation in pregnancy
Treat exactly as usual:
High-flow oxygen (target ≥94%)
Nebulised salbutamol ± ipratropium
Systemic steroids
👉 Oxygen delivery to the foetus depends entirely on maternal oxygenation.
7. Physiological changes in pregnancy (frequently tested)
Increased tidal volume → respiratory alkalosis
Increased renal clearance → lower AED levels
Reduced functional residual capacity
👉 Exam trap: Mild respiratory alkalosis is NORMAL in pregnancy.
8. Breastfeeding considerations
Most AEDs are compatible with breastfeeding
Monitor infants for sedation
Benefits generally outweigh risks
9. Contraception interactions (classic trap)
Enzyme-inducing AEDs (e.g., carbamazepine, phenytoin):
→ reduce efficacy of oral contraceptives
Consider IUD or depot contraception
10. High-yield summary list
Continue AEDs — do not stop abruptly
Avoid sodium valproate
Lamotrigine = safest commonly tested drug
Seizures are more dangerous than drugs
Continue asthma therapy
Inhaled steroids are safe
Treat acute asthma aggressively
Oxygenation is critical
Watch drug interactions with contraception
Pregnancy alters pharmacokinetics
Practical examples / mini-cases
MCQ:A 30-year-old woman with epilepsy controlled on sodium valproate wishes to become pregnant. What is the most appropriate next step?
A. Continue valproateB. Stop valproate immediatelyC. Switch to lamotrigine before conceptionD. Add folic acid onlyE. Avoid pregnancy
Answer: C. Switch to lamotrigine before conception
Explanation: Valproate carries a high risk of neural tube defects and neurodevelopmental delay. Switching to a safer alternative such as lamotrigine before conception is recommended. Abrupt cessation is unsafe due to seizure risk.
Common pitfalls (5 bullets)
❌ Stopping antiepileptics during pregnancy
❌ Forgetting valproate teratogenicity
❌ Withholding steroids in asthma exacerbation
❌ Assuming all medications are unsafe
❌ Misinterpreting normal pregnancy ABG
Practical study checklist
Memorise high-risk vs safe drugs
Focus on single-best-answer logic
Practise with Free MRCP MCQs
Simulate exam conditions via Start a mock test
Integrate with pharmacology revision
👉 Cross-link suggestion: Combine this topic with pharmacology-heavy revision posts (antiepileptics, respiratory drugs) for consolidation.

FAQs
1. Is sodium valproate contraindicated in pregnancy?
It is strongly avoided due to high teratogenic risk but may be used if no safer alternative exists and seizure control is critical.
2. Should asthma medications be stopped during pregnancy?
No. Poor asthma control poses greater risks than medications. Continue inhalers and escalate if needed.
3. What is the safest antiepileptic drug in pregnancy?
Lamotrigine is commonly regarded as the safest and is frequently tested in MRCP exams.
4. How is status epilepticus managed in pregnancy?
Management is identical to non-pregnant patients—benzodiazepines first-line, followed by second-line agents.
5. Are inhaled corticosteroids safe in pregnancy?
Yes. They are first-line preventers and should be continued to maintain asthma control.
Ready to start?
Master high-yield topics with structured practice and exam-focused learning:
Explore the MRCP Part 1 overview
Test your understanding with Free MRCP MCQs
Benchmark your progress using Start a mock test
Sources
NICE Epilepsy Guideline: https://www.nice.org.uk/guidance/ng217
NICE Asthma Guideline: https://www.nice.org.uk/guidance/ng80
RCOG Guidance: https://www.rcog.org.uk



Comments